Zinc Gluconate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Zinc Gluconate: From Zinc Deficiency Supplementation to Anemia of Prematurity
One-Sentence Summary
Zinc gluconate is a mineral compound most commonly used as a dietary/mineral supplement to correct zinc deficiency and support immune function; no formal approved-indication record is present in this evidence pack. The TxGNN model predicts potential effectiveness for Anemia of Prematurity with a very high confidence score, but this prediction is currently not supported by any clinical trials or published literature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file — no approved license or indication text available in the evidence pack (drug is unmarketed) |
| Predicted New Indication | Anemia of Prematurity |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on general pharmacological knowledge, zinc gluconate supplies bioavailable zinc and is typically used to correct zinc deficiency and support immune and wound-healing processes.
The proposed mechanistic link for this prediction is that zinc acts as a cofactor in several hematopoiesis-related enzymatic pathways, so zinc deficiency could theoretically worsen anemia. However, this link is weak and largely theoretical: anemia of prematurity is primarily driven by insufficient erythropoietin production and inadequate iron stores in preterm infants, not by zinc deficiency. No direct mechanistic, preclinical, or clinical data connecting zinc gluconate to this specific condition were found. The prediction should be treated as a hypothesis-generating model output rather than an evidence-backed candidate at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but there is zero clinical trial or literature evidence for zinc gluconate in anemia of prematurity, and the underlying mechanism conflicts with the accepted pathophysiology of the condition (erythropoietin and iron deficiency, not zinc deficiency, are the primary drivers). This is a pure model-prediction candidate (L5) with no independent corroboration.
To proceed, the following is needed:
- Resolve blocking data gap DG001: TFDA label warnings/contraindications, required before any safety pre-screen (S1) can begin
- Resolve data gap DG002: confirmed mechanism of action from DrugBank or primary literature
- Targeted preclinical or mechanistic studies specifically linking zinc status/supplementation to erythropoiesis in preterm neonates
- If mechanistic support emerges, dedicated clinical evidence (even observational) in the neonatal/preterm population before advancing beyond hypothesis stage
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.